The MedicalXpress summary of the University of California San Diego research accurately reports the core results from the Adolescent Brain Cognitive Development (ABCD) Study but falls short in contextualizing its significance amid shifting cannabis policies, rising product potency, and converging evidence from prior longitudinal cohorts. This observational study, published in Neuropsychopharmacology (2026, DOI: 10.1038/s41386-026-02395-1), followed 11,036 youth from ages 9-10 to 16-17, making it the largest longitudinal analysis of its kind in the US. It combined self-reports with biological testing (urine, saliva, hair samples) for objective THC exposure verification and rigorously adjusted for baseline cognition, family background, mental health, other substance use, and socioeconomic factors. No conflicts of interest were reported. Teens with cannabis exposure showed significantly slower gains across memory, attention, language, and processing speed. Those with confirmed THC exposure exhibited particular memory deficits over time, while a small CBD-exposed subgroup did not, underscoring THC's likely role in a developing brain still undergoing synaptic pruning and myelination. These deficits emerged even when users started with equal or superior baseline performance, suggesting cannabis interrupts normal developmental trajectories rather than merely reflecting pre-existing differences. This adds substantial weight to earlier findings, including Meier et al.'s 2012 PNAS paper from the Dunedin cohort (n=1,037 followed to age 38), which documented an approximately 8-point IQ decline among persistent adolescent-onset cannabis users that persisted into adulthood. That longitudinal observational study faced some methodological critiques around socioeconomic confounding but has been bolstered by subsequent twin-control designs showing similar patterns. A 2018 JAMA Psychiatry systematic review and meta-analysis by Scott et al. (69 studies, >8,000 participants) further synthesized evidence of small-to-moderate associations between frequent adolescent cannabis use and reduced cognitive and academic functioning, with stronger effects for earlier and heavier use. What original coverage missed is the policy urgency in an era of rapid commercialization. Mainstream reporting often centers adult recreational benefits and medical applications (e.g., RCTs supporting CBD for rare epilepsies or cannabis for chronic pain in older populations), creating a narrative imbalance that downplays adolescent vulnerability. Since statewide legalization accelerated post-2012, average THC potency has climbed from ~4% to over 20-30% in concentrates, increasing exposure intensity precisely as the ABCD data show developmental sensitivity. The study stops short of claiming definitive causation—an impossibility without randomization—but the temporal sequence, dose-response signals, biological plausibility via endocannabinoid disruption, and consistency with animal models and international cohorts (Dunedin, IMAGEN) form a compelling causal case. Unmeasured factors like genetics or peer environments remain possible, yet the adjustments and pre-use cognitive baselines substantially mitigate this. The human cost accumulates: modest lags in processing speed or memory compound into lower educational attainment, diminished occupational prospects, and higher public health burdens. As the ABCD team continues follow-up into young adulthood, future waves may clarify persistence or recovery windows. This evidence demands reframing youth protection policies—raising effective age gates toward 21-25, mandating accurate THC/CBD labeling to counter mislabeled products, funding school prevention grounded in neuroscience, and balancing public messaging that currently skews toward adult liberty and market growth. Paralleling early tobacco and opioid regulatory failures, the cannabis industry's expansion risks writing off a generation's cognitive potential for economic gains. Delaying onset remains the clearest, evidence-based safeguard for healthy brain development.